Porsolt's new AAALAC-accredited preclinical contract research facility in San Antonio, Texas, will provide non-GLP and GLP specialist pharmacology services to the pharmaceutical and biotech industry.
Commencing operations in October 2010, the facility will offer services that will complement those provided by the parent company headquartered in France and will initially focus on abuse liability assessment of new chemical and biological entities (NCEs and NBEs) in non-human primates.
Initial studies will be in the area of drug abuse/dependence, but Porsolt intends to expand to cover other major medical areas, including cognitive, pain, inflammatory, schizophrenia, and respiratory and cardiovascular pharmacology.
